Apogee Therapeutics

Apogee Therapeutics is a biotechnology company aiming to develop differentiated biological treatments for atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunological pathologies.

Atopic dermatitis is a chronic inflammatory skin condition that affects approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain, and the United Kingdom. Of these, 40% have a moderate to severe form of the disease.

The company's treatments are administered periodically, once every quarter, for disease prevention.

The company plans to conduct an initial public offering (IPO) of 15.6 million shares in the price range of $15.00 to $17.00.
_______________________________

Number of employees:

25 - 50
______________________________

Headquarters:

221 Crescent St., Building 17, Suite 102b Waltham, MA 02453